Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term [Yahoo! Finance]
Press Registration Is Now Open for the 2025 ACMG Annual Clinical Genetics Meeting [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? [Yahoo! Finance]
Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? [Yahoo! Finance]